Going Concern (removed) — Prior period disclosed auditor going-concern opinion; current filing omits this status without explanation of resolution.
Delisting (removed) — Baseline disclosed Nasdaq minimum bid price deficiency with extension through August 2025; current filing does not mention delisting risk or resolution.
Material Weakness (removed) — Two material weaknesses identified as of September 2023 were remediated by September 2024; current filing omits disclosure consistent with lifecycle closure.

NASDAQ: VERU VERU INC. 10-Q

Veru advances enobosarm obesity program with FDA clarity, raises $23M despite capital constraints

Filed May 13, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade VERU commission-free

Open an account, get a free stock.

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 5, 2026 4:15 PM